New strategy aims to cure recurrent throat cancer by cutting it out after drugs
NCT ID NCT07129772
Summary
This study is testing a new treatment plan for people whose nasopharyngeal (upper throat) cancer has come back only in the original area. Patients first receive a combination of immunotherapy (pembrolizumab) and chemotherapy to shrink the tumor. Doctors then surgically remove any remaining cancer, followed by more immunotherapy. The goal is to see if this aggressive approach provides better long-term control and a chance for a cure, allowing patients to stop ongoing drug therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Clinical Oncology, Queen Mary Hospital
Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.